Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | TACR1 | P25103 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1132894 | 1.00 | TSHR (0.48) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL1132896 | 1.00 | TSHR (0.48) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL21239569 | 0.89 | TSHR (0.56) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL12444920 | 0.84 | TSHR (0.50) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL12444919 | 0.84 | TSHR (0.50) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL3789014 | 0.83 | TSHR (0.45) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL3777580 | 0.82 | CA1 (0.50) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL2963542 | 0.82 | TSHR (0.48) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL2963549 | 0.82 | TSHR (0.48) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL3777584 | 0.82 | CA1 (0.50) | TSHRCA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079839-B2 | Methods for preparation of pharmaceutical intermediates of aliskiren | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2015-07-14 | — | — | US | disclosed |
| US-20130231509-A1 | METHODS FOR PREPARATION OF PHARMACEUTICAL INTERMEDIATES OF ALISKIREN | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2013-09-05 | — | — | US | disclosed |
| US-8084485-B2 | 6-(aminoalkyl)indazoles | VITAE PHARMACEUTICALS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110230665-A1 | SYNTHESIS OF RENIN INHIBITORS INVOLVING A CYCLOADDITION REACTION | MICKEL STUART JOHN | 2011-09-22 | — | — | US | disclosed |
| US-7973175-B2 | pyrrolidine chemical intermediates useful in the synthesis of drugs, especially enzyme inhibitors, such as Aliskiren | NOVARTIS AG (CH) | 2011-07-05 | — | — | US | disclosed |
| EP-2287153-A1 | Synthesis Of Renin Inhibitors Involving A Cycloaddition Reaction | Novartis AG (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-20100331287-A1 | 6-(Aminoalkyl)Indazoles | VITAE PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| EP-1931629-B1 | SYNTHESIS OF RENIN INHIBITORS INVOLVING A CYCLOADDITION REACTION | NOVARTIS AG (CH) | 2010-12-22 | — | — | EP | disclosed |
| US-20100298328-A1 | 1-Heterocyclylamino-2-Hydroxy-3-Amino-Omega-Arylalkanes | VITAE PHARMACEUTICALS, INC | 2010-11-25 | — | — | US | disclosed |
| US-20100274027-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-28 | — | — | US | disclosed |
| EP-1896411-A2 | PROCESS FOR PREPARING RENIN INHIBITORS | Novartis AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007123718-A1 | 1-HETEROCYCLYLAMINO-2-HYDROXY-3-AMINO-ω-ARYLALKANES | VITAE PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007120523-A2 | 6-(AMINOALKYL)INDAZOLES | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| EP-1844002-A1 | 1-ACYLAMINO-2-HYDROXY-3-AMINO-W-ARYLALKANES AS RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007039183-A1 | SYTHESIS OF RENIN INHIBITORS INVOLVING A CYCLOADDITION REACTION | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| WO-2006131304-A2 | PROCESS FOR PREPARING RENIN INHIBITORS | NOVARTIS AG (CH) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006083924-A1 | 1-ACYLAMINO-2-HYDROXY-3-AMINO-W-ARYLALKANES AS RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | ELAN PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| US-5641778-A | EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0716077-A1 | Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors | CIBA-GEIGY AG (CH) | 1996-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331287-A1 | 6-(Aminoalkyl)Indazoles | REN, AGTR1, AGTR2 | TSHR 4447/4885CA1 4586/4885CA2 598/4885 |
| US-20100298328-A1 | 1-Heterocyclylamino-2-Hydroxy-3-Amino-Omega-Arylalkanes | REN, AGTR1, AGTR2 | TSHR 3735/4885CA1 4781/4885CA2 2137/4885 |
| US-20130231509-A1 | METHODS FOR PREPARATION OF PHARMACEUTICAL INTERMEDIATES OF ALISKIREN | VRK2, VRK1, LPXN | TSHR 877/4885CA1 2021/4885CA2 967/4885 |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | APP, BACE1, BACE2 | TSHR 1945/4885CA1 32/4885CA2 251/4885 |
| US-20100274027-A1 | ORGANIC COMPOUNDS | REN, AGTR1, GRHPR | TSHR 2608/4885CA1 2064/4885CA2 366/4885 |
| US-20110230665-A1 | SYNTHESIS OF RENIN INHIBITORS INVOLVING A CYCLOADDITION REACTION | REN, AGTR1, AGTR2 | TSHR 902/4885CA1 2331/4885CA2 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.